Making genetic risk predictions more accurate for adults with acute myeloid leukemia
Official title: Towards an inclusive genomic risk classification for acute myeloid leukemia (AML)
Funded at Ohio State University · NIH-11164532 · Data updated 2026-11-12
This project is developing better genetic-based risk categories to help guide treatment decisions for adults with acute myeloid leukemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | September 18, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $652,141 |
| NIH project number | 5R01CA284595-03 |
| Project ID | NIH-11164532 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (age 21 and older) diagnosed with acute myeloid leukemia, particularly those who can provide genetic samples or allow their clinical and genomic data to be used, are the ideal candidates.
✕Less likely to help
Children and teenagers under 21 and patients looking for an immediate experimental therapy are unlikely to receive direct treatment benefit from this genetics-focused project.
What this research studies
Researchers will analyze large-scale tumor and inherited (germline) genetic data from adults with AML to see how a patient’s genetic background changes the meaning of common AML mutations. They will use statistical and computational methods to refine which gene changes predict outcomes across diverse populations and to find previously unrecognized genetic features that may drive disease or therapy resistance. The team aims to produce a more inclusive molecular risk classification so doctors can match treatment intensity more accurately to each patient. This work focuses on data analysis and genetics rather than testing new drugs.
Why it matters
Potential benefit: If successful, this could lead to more accurate, personalized treatment choices and better outcome predictions for adults with AML.
How similar studies have gone: Large genomic studies have already shaped current AML risk categories, but adjusting risk predictions based on patients' inherited genetic backgrounds is a newer and less-tested approach.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Eisfeld, Ann-Kathrin — Ohio State University
- Study coordinator: Eisfeld, Ann-Kathrin
Related research
Other NIH-funded projects on the same topics.
-
Acute Myeloid Leukemia: Improving Targeted Therapies through Genetically Defined PDX Models
Researchers are using patient-like leukemia models to develop therapies that target specific genetic features of AML to improve survival.
-
A broader genomic risk picture to guide AML treatment
AIM to refine how genetic information guides treatment decisions for adults with acute myeloid leukemia by looking at how inherited and recurrent mutations affect risk.
-
RNA Polymerase II as a Therapeutic Target in AML with RAS Activation
This project explores a new way to treat a common type of blood cancer (AML) by blocking a key machinery (RNA Polymerase II) that cancer cells use when the RAS signaling pathway is overactive.
-
SHP2 and BCL2 inhibitors together for AML growth and resistance
A patient-focused look at whether combining SHP2 inhibitors with a BCL2 inhibitor can slow or stop AML, especially in people whose disease has FLT3 or KIT mutations.
-
Targeting RNA polymerase II in AML with RAS pathway activation
This project tests drugs that block RNA polymerase II to help people whose acute myeloid leukemia has RAS pathway activation and is resistant to FLT3 inhibitors.
-
New treatment approach for myelodysplastic syndrome and acute myeloid leukemia
This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.